PolyPid Terminates Cantor Fitzgerald Sales Agreement
Ticker: PYPD · Form: 6-K · Filed: Jul 19, 2024 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Jul 19, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $8,706,775, $45,000,000, $6.4 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, legal-agreement
TL;DR
PolyPid ditches Cantor sales deal effective July 15th.
AI Summary
PolyPid Ltd. announced on July 19, 2024, that it terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. effective July 15, 2024. This agreement, originally dated July 2, 2021, allowed PolyPid to issue and sell ordinary shares.
Why It Matters
The termination of this sales agreement suggests a potential shift in PolyPid's strategy for raising capital or a change in its financing needs.
Risk Assessment
Risk Level: medium — The termination of a sales agreement can indicate underlying financial pressures or strategic changes that may impact future funding and operations.
Key Players & Entities
- PolyPid Ltd. (company) — Registrant
- Cantor Fitzgerald & Co. (company) — Sales Agent
- July 15, 2024 (date) — Effective date of termination
- July 2, 2021 (date) — Original date of sales agreement
FAQ
What was the purpose of the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald?
The agreement allowed PolyPid Ltd. to issue and sell its ordinary shares.
When did PolyPid Ltd. notify Cantor Fitzgerald of the termination?
PolyPid Ltd. delivered written notice to Cantor Fitzgerald on July 10, 2024.
What is the effective date of the termination of the sales agreement?
The termination of the sales agreement was effective as of July 15, 2024.
What type of securities could be sold under the Cantor Agreement?
Ordinary shares, no par value, could be issued and sold under the Cantor Agreement.
What is PolyPid Ltd.'s principal executive office address?
PolyPid Ltd.'s principal executive office is located at 18 Hasivim Street, Petach Tikva 495376, Israel.
Filing Stats: 351 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-07-19 16:05:18
Key Financial Figures
- $8,706,775 — ng an aggregate offering price of up to $8,706,775 (reduced from $45,000,000) from time to
- $45,000,000 — price of up to $8,706,775 (reduced from $45,000,000) from time to time through Cantor Fitzg
- $6.4 million — ion, the Company received approximately $6.4 million in net proceeds from the sales of its O
Filing Documents
- ea0209625-6k_polypid.htm (6-K) — 11KB
- 0001213900-24-063005.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PolyPid Ltd. Date: July 19, 2024 By: /s/ Dikla Czaczkes Akselbrad Name: Dikla Czaczkes Akselbrad Title: Chief Executive Officer 2